The company has received approval from the DCGI for Fasenra
(Benralizumab solution for injection in a single dose prefilled
syringe30 mg/ml) for patients with severe asthma (eosinophilic
asthma), AstraZeneca India said in a statement.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/astrazeneca-gets-dcgi-nod-for-asthma-drug/articleshow/79868216.cms
No comments:
Post a Comment